In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
no speaker photo
Speaker
Eric Velazquez
Eric Velazquez Eric Velazquez

Yale University, New Haven (United States of America)

Specialities : Chronic Heart Failure , Chronic Heart Failure, Imaging

7 presentations from this speaker

Therapy with Sacubitril-Valsartan should begin in hospital - Rebuttal

Event : Heart Failure 2019

  • Session : The Grand Debate 1: Advances in medical and interventional treatment of heart failure
  • Speaker : E Velazquez (New Haven,US), GMC Rosano (London,GB)

Therapy with Sacubitril-Valsartan should begin in hospital-Pro

Event : Heart Failure 2019

  • Session : The Grand Debate 1: Advances in medical and interventional treatment of heart failure
  • Speaker : E Velazquez (New Haven,US)

Coronary revascularisation provides no meaningful clinical benefit over optimal medical therapy in patients with stable ischaemic heart failure - CONTRA

Event : Heart Failure 2018

  • Session : GRAND DEBATE I - Drugs or interventions - The beat goes on
  • Speaker : E Velazquez (New Haven,US)

Myocardial revascularisation - When, for whom and how

Event : Heart Failure 2018

  • Session : Diagnosis and treatment of acute heart failure in acute coronary syndromes
  • Speaker : E Velazquez (New Haven,US)

Surgical revascularisation beats optimal medical therapy in ischaemic heart failure - PRO.

Event : Heart Failure 2017

  • Session : STICH (Surgical Treatment for Ischemic Heart Failure)
  • Speaker : E Velazquez (New Haven,US)

STICH at 10 years – Cardiologist approach.

Event : Heart Failure 2016

  • Session : Revascularisation strategies in ischemic heart failure
  • Speaker : E Velazquez (New Haven,US)

The effect of CABG by age in patients with heart failure: 10 year follow data from the STICHES study

Event : ESC Congress 2016

  • Session : Clinical Trial Update Coronary artery disease
  • Speaker : E Velazquez (New Haven,US)

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are